Articles On Invion (ASX:IVX)
Title | Source | Codes | Date |
---|---|---|---|
Dr Boreham’s Crucible: This is the only ASX-listed biotech in the photodynamic therapy game
When US Supreme Court judge Louis Brandeis in 1914 opined that sunlight was the best disinfectant, he was referring to the desirability of transparent legal and government processes. But he could well have been talking about the role of lig... |
Stockhead | IVX | 4 years ago |
Cancer Wars Part 1: These are the ASX small cap drugmakers that want to conquer cancer
The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small... |
Stockhead | IVX | 4 years ago |
Health: Invion may have found its break in Chinese dermatology
Invion (ASX:IVX) may have a new Chinese partner to help get its cosmetics business off the ground. The company told shareholders this morning it signed an MoU with Pavay Biotech, an established provider of dermatology treatment products in... |
Stockhead | IVX | 4 years ago |
IPO Watch: These are the top ASX debutantes of 2019
Telecommunications company Uniti Group (ASX:UWL) has topped the list of companies making their debut in 2019 with a whopping 500 per cent gain since listing. The internet service provider’s share price hit $1.50 last Friday to give it a $48... |
Stockhead | IVX | 4 years ago |
Check-up: Lasers and fatty livers won in biotech this month
Here’s our monthly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks, 92 saw their share prices fall, 32 improved and 13 were flat. >> Scroll down for a table showing the performance of small... |
Stockhead | IVX | 4 years ago |
Spies and corporate takeovers: what’s next for the China-Australia story?
Spies defecting, a foreign power secretly taking control of Australia via 5G, the stealthy infiltration of universities and CSIRO, a new arms race waged through cyber-warfare. This is not a John Le Carre novel, these are the headlines shapi... |
Stockhead | IVX | 4 years ago |
IPO Watch: Aerometrex more than doubles on ASX entry, is the 4th best first-day IPO in 2019
Aerial imaging firm Aerometrex (ASX:AMX) has had a strong start to listed life on the ASX, notching a 107 per cent gain in its first two minutes on the bourse. The company doubled its IPO price of $1 on open before edging higher still to a... |
Stockhead | IVX | 4 years ago |
Small-Cap’s Action-Packed Performance: BPL, JRL, IVX, KTG and IBX
While investing in the stock market, an investor comes across various classes of assets, such as equity and bonds. When it comes to investing in equity, there are choices like large-cap, mid-cap and small cap. Investment in small-cap comes... |
Kalkine Media | IVX | 4 years ago |
The ASX Gainers: 14D, VN8, BLT, IVX
By the closure of the market session on 29th November 2019, the benchmark index, i.e. S&P/ASX200 was at 6846 with a fall of 18 points from its last close. Besides the decline, some of the companies managed to trade in green and provided... |
Kalkine Media | IVX | 4 years ago |
10 at 10: These ASX stocks are getting jiggy with it this morning
Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte... |
Stockhead | IVX | 4 years ago |
10 at 10: These ASX stocks are heating up this morning
Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte... |
Stockhead | IVX | 4 years ago |
Invion Share Price Soars on Trial Breakthrough (ASX: IVX)
For most stocks a double-digit gain in a single day is worthy of celebration. Invion Ltd [ASX:IVX] isn’t like most stocks though… This biotech minnow has made a huge splash today. The Invion share price posting as much as a 200% gain in ear... |
MoneyMorning | IVX | 4 years ago |
Why the Invion share price rocketed 225% higher today
One of the best performers on the Australian share market on Wednesday has been the Invion Ltd (ASX: IVX) share price. The clinical-stage drug development company’s shares rocketed an incredible 225% higher at one stage today. They have si... |
Motley Fool | IVX | 4 years ago |
Health: Fricken lasers shrink ovarian cancer (also look good on sharks)
For a certain generation of investors the word ‘laser’ is indelibly tied to a Dr Evil reference. Over the last two years Invion (ASX:IVX) has been valiantly working against this association, and today says its lasers (not attached to the he... |
Stockhead | IVX | 4 years ago |
Invion unveils positive pre-clinical results for photodynamic therapy of ovarian cancer
Life-sciences company Invion (ASX: IVX) has published results from a pre-clinical study that could eventuate into an important development for women’s health. Research conducted by the Hudson Institute of Medical Research in Australia indic... |
SmallCaps | IVX | 4 years ago |
10 at 10: These ASX stocks are getting amongst it this morning
Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte... |
Stockhead | IVX | 4 years ago |
10 at 10: These ASX stocks are hitting the gas this morning
Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte... |
Stockhead | IVX | 5 years ago |
Invion and Peter MacCallum Cancer Centre to trial photodynamic therapy on penile and anal cancers
Melbourne-based Invion (ASX: IVX) will collaborate with world renowned research organisation Peter MacCallum Cancer Centre (Peter Mac) regarding pre-clinical research into the impact of Invion’s photodynamic therapy on penile and anal cance... |
SmallCaps | IVX | 5 years ago |
Prescient’s Leaders have a Rich History of taking Drugs from Bench to Bedside
Prescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is into the development of personalised medicines for the treatment of multiple cancers. The company aims to develop novel drugs that work on th... |
Kalkine Media | IVX | 5 years ago |
IPO Watch: Investors are choosing established stocks over new floats
It has been a slow start to the new fiscal year, with the list of planned IPOs thinning out. There’s just seven companies on the ASX’s list of IPOs hoping to hit the boards this month and next. According to the bourse’s market stats, initia... |
Stockhead | IVX | 5 years ago |
Twiggy Forrest-backed Invex Therapeutics is enjoying life so far as a listed company
Biotech company Invex Therapeutics (ASX:IVX) got off to a flyer when it joined the ASX boards on Friday. The company raised $12m at IPO via the issuance of 30m shares at 40c each. The stock commenced trading at 60c and closed on Friday at $... |
Stockhead | IVX | 5 years ago |